Opinion: Marijuana could curb reliance on opioids for pain relief

The opioid epidemic in the United States is taxing the clinicians across the country. In an effort to reduce the 650,000 opioid prescriptions filled on a daily basis, phsycians need an alternative for pain relief. Esther K. Choo, MD, MPH, with the Oregon Health & Science University in Portland and two colleagues have written a letter in JAMA urging for a universal standing on cannabis as one solution to the opioid epidemic.

While the federal agencies of America call for a weening off of opioids, they fail to fill the gap of pain relievers it will leave behind. Opioid are effecting millions across the nation, and with so many prescriptions being filled, a real need exists to provide responsible pain relief. With 25 states and the District of Columbia legalizing cannabis for medical use, the solution could be medical marijuana, according to the authors.

“The mandated transition to limit use of opioids, paired with the current climate around liberalizing cannabis, may lead to patients’ formal and informal substitution of cannabis for opioids,” write Choo et al. “Observational studies have found that state legalization of cannabis is associated with a decrease in opioid addiction and opioid-related overdose deaths.”

Read the full article on JAMA by clicking the link below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.